Agilent Technologies (NYSE:A) Stock Price Expected to Rise, TD Cowen Analyst Says

Agilent Technologies (NYSE:A) had its price target upped by investment analysts at TD Cowen from $155.00 to $180.00 in a research note issued on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the medical research company’s stock. TD Cowen’s price target would indicate a potential upside of 14.30% from the stock’s current price.

Other equities research analysts have also issued reports about the stock. Morgan Stanley increased their target price on shares of Agilent Technologies from $160.00 to $175.00 and gave the stock an “overweight” rating in a report on Wednesday, August 12th. Barclays increased their price objective on Agilent Technologies from $145.00 to $150.00 and gave the company an “overweight” rating in a research note on Wednesday, June 24th. Robert W. Baird upped their price target on Agilent Technologies from $155.00 to $156.00 and gave the stock an “outperform” rating in a report on Tuesday, May 26th. Bank of America raised Agilent Technologies from a “neutral” rating to a “buy” rating and reduced their price target for the company from $150.00 to $145.00 in a research report on Thursday, May 28th. Finally, HSBC lowered their price objective on Agilent Technologies from $180.00 to $165.00 and set a “buy” rating for the company in a research report on Wednesday, June 3rd. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $165.06.

Agilent Technologies Trading Up 1.5%

Agilent Technologies stock traded up $2.40 during midday trading on Thursday, reaching $157.48. 1,033,014 shares of the stock traded hands, compared to its average volume of 2,227,299. The firm has a market cap of $44.48 billion, a PE ratio of 31.63, a price-to-earnings-growth ratio of 2.73 and a beta of 1.25. The company has a current ratio of 2.10, a quick ratio of 1.62 and a debt-to-equity ratio of 0.43. The company has a 50-day simple moving average of $139.16 and a two-hundred day simple moving average of $126.65. Agilent Technologies has a 12-month low of $108.35 and a 12-month high of $163.75.

Agilent Technologies (NYSE:A) last issued its quarterly earnings results on Wednesday, August 26th. The medical research company reported $1.62 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.49 by $0.13. Agilent Technologies had a net margin of 19.55% and a return on equity of 24.33%. The company had revenue of $1.88 billion for the quarter, compared to analyst estimates of $1.84 billion. During the same period in the prior year, the firm earned $1.37 earnings per share. The business’s revenue for the quarter was up 8.1% compared to the same quarter last year. Agilent Technologies has set its Q4 2026 guidance at 1.710-1.740 EPS and its FY 2026 guidance at 6.180-6.210 EPS. Research analysts expect that Agilent Technologies will post 6.05 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Agilent Technologies

A number of hedge funds and other institutional investors have recently made changes to their positions in A. California State Teachers Retirement System grew its stake in shares of Agilent Technologies by 12,343.3% in the 2nd quarter. California State Teachers Retirement System now owns 54,577,058 shares of the medical research company’s stock valued at $7,249,471,000 after purchasing an additional 54,138,451 shares during the last quarter. State Street Corp raised its stake in shares of Agilent Technologies by 1.9% during the fourth quarter. State Street Corp now owns 12,681,792 shares of the medical research company’s stock worth $1,725,611,000 after purchasing an additional 241,029 shares during the last quarter. Wellington Management Group LLP raised its stake in shares of Agilent Technologies by 2.7% during the second quarter. Wellington Management Group LLP now owns 7,454,686 shares of the medical research company’s stock worth $990,206,000 after purchasing an additional 198,253 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Agilent Technologies by 0.3% during the fourth quarter. Geode Capital Management LLC now owns 7,425,861 shares of the medical research company’s stock worth $1,006,519,000 after purchasing an additional 25,139 shares during the period. Finally, Deutsche Bank AG lifted its holdings in shares of Agilent Technologies by 17.1% during the second quarter. Deutsche Bank AG now owns 7,008,634 shares of the medical research company’s stock worth $930,957,000 after purchasing an additional 1,024,516 shares during the period. Hedge funds and other institutional investors own 87.41% of the company’s stock.

Agilent Technologies News Roundup

Here are the key news stories impacting Agilent Technologies this week:

• Positive Sentiment: Quarterly results exceeded expectations. Agilent reported revenue of $1.88 billion, up 8.1% year over year and above the $1.84 billion consensus estimate. Adjusted earnings were $1.62 per share, versus expectations of $1.49, while reported net income rose to $362 million from $336 million a year earlier. Agilent Reports Third-Quarter Fiscal Year 2026 Financial Results
• Positive Sentiment: Profitability and cash generation improved. Operating profit increased 23.3% to $444 million, and operating cash flow climbed 43.4% to $519 million. The results suggest expanding margins and stronger execution, supporting the positive market reaction. Agilent Technologies: Q3 Growth, Expanding Margins, And Raised Guidance
• Positive Sentiment: Agilent raised its fiscal 2026 forecast. The company now expects full-year adjusted EPS of $6.18-$6.21, above the approximately $6.06 consensus, and revenue of about $7.5 billion, also ahead of expectations. Fourth-quarter EPS guidance of $1.71-$1.74 is at or above estimates. Management cited improving demand for medical, laboratory and drug-development equipment. Agilent raises annual profit forecast on improving lab tools demand
• Positive Sentiment: Royal Bank of Canada raised its price target. RBC lifted its target from $155 to $185 and reaffirmed an “outperform” rating, providing additional analyst support following the earnings beat. Benzinga
• Neutral Sentiment: At roughly $158 per share, Agilent is trading near its 52-week high and at a reported P/E ratio above 31, indicating that investors are already assigning a premium to the company’s improving growth outlook.

About Agilent Technologies

Agilent Technologies is a global provider of scientific instrumentation, consumables, software and services for laboratories across the life sciences, diagnostics and applied chemical markets. The company’s product portfolio includes analytical instruments such as liquid and gas chromatographs, mass spectrometers, spectroscopy systems, and laboratory automation solutions, together with reagents, supplies and informatics tools that support measurement, testing and data analysis workflows. Agilent also offers instrument maintenance, qualification and laboratory services designed to help customers improve productivity and comply with regulatory requirements.

Founded as a corporate spin-off from Hewlett?Packard in 1999, Agilent has evolved through a combination of strategic restructuring and acquisitions to concentrate on life sciences, diagnostics and applied laboratories.